Novartis, Savient drugs nixed by NICE; Vivus nabs EU approval for Spedra; Aussies aim for sunshine on pharma payments;

@FiercePharma: India suspends Actos on safety concerns. Two other (very old) drugs, too. Report | Follow @FiercePharma

@EricPFierce: FDA goes from passive to aggressive on compounders. I wonder how long before certain Congressmen complain. More | Follow @EricPFierce

@CarlyHFierce: Proxy fight heating up at Vivus... First Manhattan announces search for new CEO candidates. Yesterday's story | Follow @CarlyHFierce

> Novartis' ($NVS) cancer drug Jakavi and Savient's ($SVNT) gout drug Krystexxa got the cold shoulder from U.K. cost-effectiveness watchdogs, who said the drugs were too expensive for use by the National Health Service. Report

> Vivus ($VVUS) won European approval for its erectile dysfunction drug Spedra, more than a year after its clearance from FDA under the brand name Stendra; the company hasn't yet launched in either market. Report

> Medicines Australia, an industry group, unveiled a proposal to require drugmakers to disclose payments to doctors, whether in the form of cash, stock options or food, beginning in 2015. Report

> Ireland's new law encouraging generic use and creating a system of reference pricing went into effect. Report

> India's Dr. Reddy's rolled out its version of the GlaxoSmithKline ($GSK) seizure drug Lamictal in the U.S. Report

> Moody's Japan assigned a (P)Aa3 rating to Takeda Pharmaceutical's shelf registration, which amounts to 250 billion yen, or about $2.54 billion. Release

> Alexion Pharmaceuticals ($ALXN) won an orphan-drug designation for Soliris to treat neuromyelitis optica; the drug is already approved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Report

Medical Device News

@FierceMedDev: St. Jude takes to Japan with MRI-safe pacer. Story | Follow @FierceMedDev

@DamianFierce: For CROs big and small, you're only as good as your reputation. The view from  DIA 2013. Editor's corner | Follow @DamianFierce

@MichaelGFierce: SEC hammers imaging company, CEO with fraud charges. Report | Follow @MichaelGFierce

> Medtronic warns over pump tied to 14 deaths. Story

> Navidea keys up Alzheimer's Dx agent for Phase III. News

Biotech News

@FierceBiotech: Big Data guru Atul Butte's NuMedii scores $3.5M VC round for 'digital' drug research. FierceBiotech IT story | Follow @FierceBiotech

 @JohnCFierce: Stanley Family Foundation spearheads a $21M round for Heptares - (GPCRs). News | Follow @JohnCFierce

@RyanMFierce: J&J's pharma chairman lands 'more deals' in Boston innovation push. Report | Follow @RyanMFierce

> Celgene jumps into blood-cancer race with J&J, adding $818M MorphoSys deal. Report

> Reverse' DNA vaccine bursts into the spotlight with promising Type 1 diabetes data. News

> Genentech eyes 'breakthrough' cancer immunotherapies in pact with U.K. biotech. Story

> U.S. hands out retirement papers to chimps used for research. Article

Pharma Manufacturing News

> Aspen, Merck deal includes API plants in U.S., Netherlands. Article

> Roche sets out strict expectations for contractors. Report

> Drugmakers more concerned with quality than price in picking CMOs. Item

> FDA spells out its expectations for crude heparin. More

Vaccines News

> Japan faces vaccine shortage in struggle to control rubella. Report

> ACIP rules on GSK, Novartis and Sanofi vaccines. Story

> Corruption alleged as Indian vaccine shortage continues. Item

> Type 1 diabetes vaccine impresses in early study. News

> Takeda tackling norovirus in bid to grow vaccine biz. Article

And Finally... While drugmakers were scouring for counterfeit meds, fake foods have become an epidemic. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.